Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status

Brain Tumor Pathology

Volumn 29, Issue 4, 2012, Pages 183-191

  Ohno, Makoto ^a   Narita, Yoshitaka ^a   Miyakita, Yasuji ^a   Okita, Yoshiko ^a   Matsushita, Yuko ^a   Yoshida, Akihiko ^a   Fukushima, Shintaro ^a   Ichimura, Koichi ^b   Kayama, Takamasa ^a   Shibui, Soichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Astrocytoma; Glioblastoma; IDH; Malignant progression; Oligodendroglioma

Indexed keywords

CARBOPLATIN; ENZYME ANTIBODY; ETOPOSIDE; INTERFERON; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 1 ANTIBODY; ISOCITRATE DEHYDROGENASE 2; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN NECROSIS; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE ASTROCYTOMA; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; MALE; MONOTHERAPY; OLIGODENDROGLIOMA; SEQUENCE ANALYSIS; ADOLESCENT; BRAIN TUMOR; CHILD; DISEASE COURSE; DNA SEQUENCE; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876434677     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-012-0113-1     Document Type: Article

References (27)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer (IARC), Lyon
2. Jeuken JW, Sprenger SH, Vermeer H et al (2002) Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 96:559-564 (Pubitemid 34230212)
3. Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177-183
4. Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419-5426 (Pubitemid 46623175)
5. Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
6. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474
7. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347
8. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
9. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
10. Kim YH, Nobusawa S, Mittelbronn M et al (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708-2714
11. Ichimura K. (2012) Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol
12. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932-941
13. Capper D, Reuss D, Schittenhelm J et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121:241-252
14. Chaichana KL, McGirt MJ, Laterra J et al (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112:10-17
15. Jaeckle KA, Decker PA, Ballman KV et al (2010) Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol 104:253-259
16. Lavon I, Zrihan D, Zelikovitch B et al (2007) Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 13:1429-1437 (Pubitemid 46450432)
17. McCormack BM, Miller DC, Budzilovich GN et al (1992) Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery 31:636-642 discussion 642
18. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489 (Pubitemid 40781150)
19. Schmidt MH, Berger MS, Lamborn KR et al (2003) Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 98:1165-1169 (Pubitemid 36617915)
20. van den Bent MJ, Afra D, de Witte O et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990 (Pubitemid 41323034)
21. Kreth FW, Faist M, Rossner R et al (1997) Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 79:370-379 (Pubitemid 27029902)
22. Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784-1791 (Pubitemid 24301834)
23. Claus EB, Horlacher A, Hsu L et al (2005) Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103:1227-1233 (Pubitemid 40328094)
24. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
25. Coons SW, Johnson PC, Scheithauer BW et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393 (Pubitemid 27143246)
26. Labussiere M, Idbaih A, Wang XW et al (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890
27. Giannini C, Burger PC, Berkey BA et al (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369 (Pubitemid 351782844)